Cold agglutinin disease (CAD) a rare and chronic autoimmune hemolytic anemia.

CAD is caused by antibodies called cold agglutinins binding to the surface of red blood cells, which starts a process that causes the body’s immune system to mistakenly attack healthy red blood cells causing their rupture (hemolysis).

Patients with CAD may experience severe anemia, which can result in debilitating fatigue, weakness, shortness of breath, light-headedness, chest pain, irregular heartbeat, and other potential complications.

Enjaymo is the first and only approved treatment for people with CAD. It works by inhibiting the activation of the complement cascade in the immune system to prevent the abnormal destruction of healthy red blood cells.

Drugs used to treat Cold Agglutinin Disease